Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]
Bopp AR +10 more
europepmc +1 more source
Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. [PDF]
Lee KW +5 more
europepmc +1 more source
Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]
Zhao Y +9 more
europepmc +1 more source
Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]
Patel JN, Singh J, Ghosh N.
europepmc +1 more source
The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. [PDF]
Yang S +7 more
europepmc +1 more source
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. [PDF]
Huntington SF +7 more
europepmc +1 more source
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. [PDF]
Montalban X +13 more
europepmc +1 more source
Heterogeneity in Infection Reporting Across Covalent Bruton Tyrosine Kinase Inhibitor Studies in B-Cell Malignancies: A Systematic Review. [PDF]
Kiyani M, Clanahan O, Silverman MA.
europepmc +1 more source
Case Report: Relapsed acquired hemophilia A following prednisone-rituximab therapy successfully treated with orelabrutinib. [PDF]
Guo Y +5 more
europepmc +1 more source
CNS <i>Neoscytalidium dimidiatum</i>: A Rare Cause of Fungal Brain Abscess. [PDF]
Khojah AM +4 more
europepmc +1 more source

